Precision BioSciences (DTIL)

Executive Summary

Precision BioSciences is a clinical-stage biotechnology company leveraging its proprietary ARCUS genome editing platform to develop potentially curative therapies for hard-to-treat genetic and infectious diseases. The company’s lead programs include PBGENE-DMD (Phase 1/2) for Duchenne Muscular Dystrophy (DMD), which uses in vivo gene editing to restore dystrophin expression, and PBGENE-HBV (Phase 1) for chronic hepatitis B, aimed at eliminating covalently closed circular DNA (cccDNA) from infected hepatocytes. Additionally, a pre-clinical HBV program is ongoing. Financially, Precision is publicly traded (NASDAQ: DTIL) with an estimated valuation of ~$198 million and 25.8 million shares outstanding. Despite early-stage clinical data, the ARCUS platform offers unique advantages in specificity and size, potentially enabling safer and more effective in vivo editing. However, the company faces typical biotech risks, including clinical trial execution and competitive landscape.

Upcoming Catalysts (preview)

• Q2 2027PBGENE-DMD Phase 1/2 interim safety and efficacy data40% success
• Q4 2026PBGENE-HBV Phase 1 initial data readout50% success
• Q3 2026PBGENE-HBV pre-clinical IND filing or partnership update60% success